Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery system.

Lemarié F, Croft DR, Tate RJ, Ryan KM, Dufès C.

Biomaterials. 2012 Mar;33(9):2701-9. doi: 10.1016/j.biomaterials.2011.12.019.

PMID:
22200536
2.

Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA.

Koppu S, Oh YJ, Edrada-Ebel R, Blatchford DR, Tetley L, Tate RJ, Dufès C.

J Control Release. 2010 Apr 19;143(2):215-21. doi: 10.1016/j.jconrel.2009.11.015.

PMID:
19944722
3.

Transferrin-bearing polypropylenimine dendrimer for targeted gene delivery to the brain.

Somani S, Blatchford DR, Millington O, Stevenson ML, Dufès C.

J Control Release. 2014 Aug 28;188:78-86. doi: 10.1016/j.jconrel.2014.06.006.

PMID:
24933602
4.

Enhanced gene expression in the brain following intravenous administration of lactoferrin-bearing polypropylenimine dendriplex.

Somani S, Robb G, Pickard BS, Dufès C.

J Control Release. 2015 Nov 10;217:235-42. doi: 10.1016/j.jconrel.2015.09.003.

PMID:
26362697
5.

Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo.

Emmrich S, Wang W, John K, Li W, Pützer BM.

Mol Cancer. 2009 Aug 11;8:61. doi: 10.1186/1476-4598-8-61.

6.

Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes.

Lim LY, Koh PY, Somani S, Al Robaian M, Karim R, Yean YL, Mitchell J, Tate RJ, Edrada-Ebel R, Blatchford DR, Mullin M, Dufès C.

Nanomedicine. 2015 Aug;11(6):1445-54. doi: 10.1016/j.nano.2015.04.006.

7.

A combination treatment with SAHA and ad-p63/p73 shows an enhanced anticancer effect in HNSCC.

Shim SH, Lee CT, Lee JJ, Kim SY, Hah JH, Heo DS, Sung MW.

Tumour Biol. 2010 Dec;31(6):659-66. doi: 10.1007/s13277-010-0083-z.

PMID:
20665144
9.

Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes on prostate carcinomas.

Al Robaian M, Chiam KY, Blatchford DR, Dufès C.

Nanomedicine (Lond). 2014 Apr;9(4):421-34. doi: 10.2217/NNM.13.25.

PMID:
24910874
10.

Adenovirus-mediated TA-p73beta gene transfer increases chemosensitivity of human malignant melanomas.

Tuve S, Racek T, Niemetz A, Schultz J, Soengas MS, Pützer BM.

Apoptosis. 2006 Feb;11(2):235-43.

11.

Novel tocotrienol-entrapping vesicles can eradicate solid tumors after intravenous administration.

Fu JY, Zhang W, Blatchford DR, Tetley L, McConnell G, Dufès C.

J Control Release. 2011 Aug 25;154(1):20-6. doi: 10.1016/j.jconrel.2011.04.015.

PMID:
21539872
12.

1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model.

Ma Y, Yu WD, Hershberger PA, Flynn G, Kong RX, Trump DL, Johnson CS.

Mol Cancer Ther. 2008 Sep;7(9):3047-55. doi: 10.1158/1535-7163.MCT-08-0243.

13.

p73 beta-expressing recombinant adenovirus: a potential anticancer agent.

Das S, Nama S, Antony S, Somasundaram K.

Cancer Gene Ther. 2005 Apr;12(4):417-26.

PMID:
15678153
14.

Tumor regression after systemic administration of tocotrienol entrapped in tumor-targeted vesicles.

Fu JY, Blatchford DR, Tetley L, Dufès C.

J Control Release. 2009 Dec 3;140(2):95-9. doi: 10.1016/j.jconrel.2009.08.017.

PMID:
19709637
15.

Prenyl Ammonium Salts--New Carriers for Gene Delivery: A B16-F10 Mouse Melanoma Model.

Grecka E, Statkiewicz M, Gorska A, Biernacka M, Grygorowicz MA, Masnyk M, Chmielewski M, Gawarecka K, Chojnacki T, Swiezewska E, Malecki M.

PLoS One. 2016 Apr 18;11(4):e0153633. doi: 10.1371/journal.pone.0153633.

16.

PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.

Saha MN, Jiang H, Yang Y, Reece D, Chang H.

Mol Cancer Ther. 2013 Nov;12(11):2331-41. doi: 10.1158/1535-7163.MCT-12-1166.

17.

Enhanced transfection efficiency and targeted delivery of self-assembling h-R3-dendriplexes in EGFR-overexpressing tumor cells.

Li J, Li S, Xia S, Feng J, Zhang X, Hao Y, Chen L, Zhang X.

Oncotarget. 2015 Sep 22;6(28):26177-91. doi: 10.18632/oncotarget.4614.

18.

Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors.

Dufès C, Keith WN, Bilsland A, Proutski I, Uchegbu IF, Schätzlein AG.

Cancer Res. 2005 Sep 15;65(18):8079-84.

19.

Antitumor activity of the tea polyphenol epigallocatechin-3-gallate encapsulated in targeted vesicles after intravenous administration.

Lemarié F, Chang CW, Blatchford DR, Amor R, Norris G, Tetley L, McConnell G, Dufès C.

Nanomedicine (Lond). 2013 Feb;8(2):181-92. doi: 10.2217/nnm.12.83.

PMID:
22891867
20.

Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins.

Park JS, Kim EJ, Lee JY, Sin HS, Namkoong SE, Um SJ.

Int J Cancer. 2001 Mar 15;91(6):822-7.

Supplemental Content

Support Center